Track Provention Bio's long-term debt ($24M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2022), PRVB shows a long-term debt of $24M. That compares with $590K in the prior-year period — up 3952.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PRVB's long-term debt is now $24M (was $590K) — a 3952.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Provention Bio is outperforming or lagging.
Tracking PRVB's long-term debt over time shows whether Provention Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $590K in the prior-year period — up 3952.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Provention Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $24M) with ownership activity and broader fundamentals.
Provention Bio's long-term debt is $24M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.